On June 11, 2025, Cabaletta Bio, Inc. filed an 8-K reporting the entry into an underwriting agreement for an offering of 39.2 million shares and additional warrants, expecting net proceeds of about $94 million to fund clinical development and operations. The offering is anticipated to close on June 12, 2025.